後線治療Phase 3 RCTLancet 2025來源:人工整理

Zanzalintinib + Atezolizumab vs Regorafenib (3L+ MSS/pMMR mCRC)

關鍵結果ITT mOS 10.9 vs 9.4 mo (HR 0.80, 95% CI 0.69–0.93, p=0.0045); no liver mets interim HR 0.79 (p=0.087, NS); G3+ TRAEs 60% vs 37%

首個在 MSS/pMMR mCRC 以免疫療法組合達 Phase 3 OS 獲益(vs regorafenib),突破 MSS 免疫治療壁壘,但毒性顯著較高。

詳細證據整理

Zanzalintinib plus Atezolizumab versus Regorafenib in Refractory Metastatic Colorectal Cancer (STELLAR-303)

Journal: Lancet 2025
DOI: 10.1016/S0140-6736(25)02025-2
PMID: 41130252
Study: STELLAR-303 (Phase 3 RCT)
Note: Full text is available at https://doi.org/10.1016/S0140-6736(25)02025-2.

Abstract

Design: Global Phase 3 randomized controlled trial in patients with refractory (third-line or later) microsatellite-stable / mismatch-repair-proficient (MSS/pMMR) metastatic colorectal cancer (mCRC) who had progressed on or were intolerant to standard therapies.

Arms: Patients (N = 901) were randomized to:

  • Experimental: zanzalintinib (a multitargeted tyrosine kinase inhibitor of MET/VEGFR/AXL/MER/RET) + atezolizumab (anti-PD-L1)
  • Control: regorafenib

Primary endpoint: Overall survival (OS) in the intention-to-treat (ITT) population and OS in the subset of patients without liver metastases.

Key Results

Endpoint Zanzalintinib + Atezolizumab Regorafenib
Median OS (ITT) 10.9 months 9.4 months
OS HR (ITT) 0.80 (95% CI 0.69–0.93; P=0.0045)
OS HR (no liver metastases, interim) 0.79 (P=0.087, not significant; final analysis pending)
Grade ≥3 treatment-related AEs 60% 37%

Conclusions

STELLAR-303 is the first Phase 3 trial to demonstrate a statistically significant overall survival benefit for an immunotherapy-based combination versus regorafenib in MSS/pMMR metastatic colorectal cancer, challenging the long-held view that MSS mCRC does not respond to immune checkpoint inhibition. Zanzalintinib is hypothesized to remodel the tumor immune microenvironment, acting synergistically with PD-L1 blockade. The OS improvement (HR 0.80) is modest relative to current third-line standards such as SUNLIGHT (TAS-102 + bevacizumab, HR 0.61) and FRESCO-2 (fruquintinib, HR 0.66), and toxicity was notably higher (Grade ≥3 treatment-related AEs 60% vs 37%). The no-liver-metastases subset did not reach significance at interim analysis. Despite these caveats, the study is an important milestone that may drive a new wave of research into later-line immunotherapy for MSS mCRC.

本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。

相關評論

讀者討論

讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。

載入留言中…

  • Meta-analysisDig Liver Dis 2025來源:人工整理

    FTD-TPI±bev/RAM vs fruquintinib vs Rego160 vs Rego80+ vs BSC (NMA)

    FTD-TPI+bev 優於其他所有方案(vs fruquintinib OS HR 0.62;vs Rego160 OS HR 0.57);曾接受 anti-VEGF 者 FTD-TPI+bev、fruquintinib、Rego80+ 療效相當

    3L mCRC NMA 確立 FTD-TPI+bev 整體最佳地位;anti-VEGF 前治療者可選 fruquintinib 或 Rego80+

  • Phase 2Nat Commun 2025來源:人工整理

    Regorafenib + Sintilimab (MSS mCRC, salvage)

    mOS 14.1m, mPFS 4.1m, ORR 21.4%, DCR 63.1%, DoR 13.0m; RAS/RAF wt 亞組 mOS 23.3m vs 突變型 12.1m

    Regorafenib + sintilimab 用於 MSS mCRC 後線治療:mOS 14.1m、ORR 21.4%(RAS/RAF wt 亞組 mOS 達 23.3m),為該難治族群提供重要概念驗證。

看 後線治療 的全部文獻